Pioneering the next generation of treatment solutions
We support innovation across the continuum of care, to help to develop new technologies, treatments and vaccines.
Johnson & Johnson Reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study
Based on final Phase 1 data published in JAMA, prime-boost Ebola vaccine regimen induced antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. Vaccine development partners include U.S. National Institutes of Health, Europe’s Innovative Medicines Initiative, Bavarian Nordic, London School of Hygiene &Tropical Medicine, University of Oxford, Inserm and BARDA.
Johnson & Johnson Names Winners of First Africa Innovation Challenge
Competition Part of Company’s Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent
3 entrepreneurs, 3 big ideas: Meet the winners of the Johnson & Johnson Africa Innovation Challenge
From helping stop the spread of disease in public bathrooms in Uganda to supporting local farmers in Liberia, these savvy troubleshooters have devised simple healthcare solutions with serious impact.
U.S. FDA Approves Vermox™ Chewable (Mebendazole) For Treatment of Children and Adults With Roundworm and Whipworm Infections
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced today that the U.S. Food and Drug Administration (FDA) has approved VERMOXTM CHEWABLE (mebendazole chewable 500mg tablets) for the treatment of patients one year of age and older with gastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm).
The International Partnership for Microbicides’s Ring Study results published in The New England Journal of Medicine
Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.
First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI
Phase IIb data presented at the Conference on Retroviruses and Opportunistic Infections 2016 demonstrated comparable antiviral activity between two injectable HIV medicines given together and the 3-drug oral antiretroviral therapy.
IPM study results show promise in protecting women against HIV
The International Partnership for Microbicides (IPM) announced results of The Ring Study and ASPIRE, demonstrating that a monthly vaginal ring containing Janssen’s antiretroviral drug, dapivirine, can safely help prevent HIV-1 infection in women.
New York Times report on The Ring Study and ASPIRE
The New York Times reported on the results of The Ring Study and ASPIRE demonstrating that a vaginal ring containing Janssen’s antiretroviral drug helped lower HIV rates in African women.
Bold goal of an HIV vaccine is motivating great science
In this Devex blog, Johnson & Johnson leadership discusses the potential impact of an HIV vaccine.
Expanding access to HIV medicine for children
Janssen expanded policy aimed at enhancing access to its HIV medicine, darunavir, to children in 128 low- and middle-income countries.
GlobalPost.com reports on IPM partnership to protect women from HIV
Executives from the International Partnership for Microbicides (IPM) and Johnson & Johnson discuss a new agreement to help ensure women have the tools to protect themselves from HIV infection in GlobalPost.com.
Partnering with IPM to protect women from HIV
Janssen announced an expanded collaboration with the International Partnership for Microbicides (IPM) to develop, commercialize and deliver its HIV medicine, dapivirine, to women in lower income communities.
Our commitment to improving the health of women and children infographic
Learn about Johnson & Johnson’s commitment to improve the health of women and children in five key areas.
Janssen Wins Prestigious International Prix Galien Award for MDR-TB Treatment
Janssen Pharmaceuticals, Inc. received the prestigious International Prix Galien, recognizing excellence in scientific innovation to improve human health.
This new tuberculosis drug could change the world
Johnson & Johnson was named to Fortune’s 2016 Change the World list for its efforts to combat multi drug-resistant tuberculosis with the first new treatment for TB in more than 40 years.
R&D and innovation in India
Janssen India leadership discusses new initiative to combat MDR-TB in India with The Hindu Business Line.
Johnson & Johnson and Janssen support new TB initiative in India
Times of India reports on launch of a new program to help combat MDR-TB and XDR-TB in India.
Evaluating MDR-TB treatment regimens with The Union
Janssen announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO® (bedaquiline) in an ongoing study that explores a standardized treatment regimen for patients with MDR-TB.
Harvard Medical School grant to combat pediatric TB
Janssen provided a grant to Harvard Medical School to develop a two-year research, policy and advocacy program to improve access to TB diagnosis and treatment with a focus on children.
FDA approves Janssen Pharmaceutical’s VERMOX™ CHEWABLE
VERMOX™ CHEWABLE treats patients one year of age and older with gastrointestinal infections caused by roundworm and whipworm infections.
Ebola vaccine regimen submitted for WHO Emergency Use Assessment and Listing
If the World Health Organization grants the listing, this will accelerate the global availability of Janssen’s investigational Ebola prime-boost vaccine regimen if another Ebola crisis occurs.
Janssen antidepressant receives FDA breakthrough therapy designation
Esketamine, Janssen’s investigational antidepressant medication for major depressive disorder with imminent risk of suicide, received FDA Breakthrough Therapy Designation.
FDA grants priority review to NDA for chewable mebendazole tablet
The U.S. Food and Drug Administration granted Priority Review designation to Janssen’s new drug application for a chewable tablet formulation of mebendazole, which treats and prevents soil-transmitted helminthiasis, also known as intestinal worm infestations.
FDA grants emergency use authorization to ebola diagnostic
The Idylla™ Ebola Virus Triage Test, jointly developed by Janssen Diagnostics, a division of Janssen Pharmaceutica, Biocartis NV (Biocartis), and the Belgium Institute of Tropical Medicine, was granted Emergency Use Authorization by the U.S. Food and Drug
Janssen submits NDA for mebendazole chewable tablet
Janssen announced the submission of a New Drug Application to the FDA for a 500mg mebendazole chewable tablet to treat adults and children aged one year or older with intestinal worm infections.
JAMA publishes positive phase 1 data for Ebola vaccine regimen
The first clinical data for an Ebola prime-boost vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson have been published in JAMA: The Journal of the American Medical Association.
Developing tools to end Ebola
Peter Piot, who co-discovered the Ebola virus in 1976, and Johnson & Johnson leadership discuss the urgent need to focus resources on finding vaccines and therapies to help fight Ebola with The Guardian.
The International Partnership for Microbicides’s Ring Study results published in The New England Journal of Medicine
Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.a
Bloomberg: Ebola vaccine has promise
Bloomberg reports on the positive immune response demonstrated in a Phase 1 clinical study of our Ebola prime-boost vaccine regimen being developed with help from global partners